Enteric-coated aspirin in cardiac patients: Is it less effective than plain aspirin?

被引：8

作者：

Jirmar, Radovan ^{[1
,2
,3
]}

Widimsky, Petr ^{[1
,2
]}

机构：

[1] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Cardioctr, Dept Internal Med Cardiol 3, Prague, Czech Republic

[2] Charles Univ Prague, Fac Med 3, Prague, Czech Republic

[3] Cardiac Outpatient Dept, Prague 10, Czech Republic

来源：

COR ET VASA | 2018年 / 60卷 / 02期

关键词：

Aspirin; Enteric coating; Coronary heart disease; Resistance;

D O I：

10.1016/j.crvasa.2017.05.011

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The aim of this review article is to make readers aware of the risk of an inadequate antiplatelet effect of enteric-coated formulations of aspirin. Judging by data from studies published to date and exploring the efficacy of various aspirin formulations, there exist sufficient evidences only of a plain form of aspirin absorbed in the stomach. The implication is that patients with coronary heart disease (CHD) should be treated exclusively with the standard formulation of aspirin. (c) 2017 The Czech Society of Cardiology. Published by Elsevier Sp. z o. o. All rights reserved.

引用

页码：E165 / E168

页数：4

共 21 条

[1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[2]

[Anonymous], 1990, LANCET, V336, P65

[3]

[Anonymous], 1988, LANCET, V2, P349

[4] Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus [J].

Bhatt, Deepak L. ;

Grosser, Tilo ;

Dong, Jing-fei ;

Logan, Douglas ;

Jeske, Walter ;

Angiolillo, Dominick J. ;

Frelinger, Andrew L., III ;

Lei, Lanyu ;

Liang, Juan ;

Moore, Jason E. ;

Cryer, Byron ;

Marathi, Upendra .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (06) :603-612

[5] Antiplatelet therapy-A pharmacologist's perspective [J].

Bultas, Jan .

COR ET VASA, 2013, 55 (02) :E86-E94

[6]

Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1

[7] Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers [J].

Cox, Dermot ;

Maree, Andrew O. ;

Dooley, Michelle ;

Conroy, Ronan ;

Byrne, Michael F. ;

Fitzgerald, Desmond J. .

STROKE, 2006, 37 (08) :2153-2158

[8] Aspirin A Historical and Contemporary Therapeutic Overview [J].

Fuster, Valentin ;

Sweeny, Joseph M. .

CIRCULATION, 2011, 123 (07) :768-778

[9] Drug Resistance and Pseudoresistance An Unintended Consequence of Enteric Coating Aspirin [J].

Grosser, Tilo ;

Fries, Susanne ;

Lawson, John A. ;

Kapoor, Shiv C. ;

Grant, Gregory R. ;

FitzGerald, Garret A. .

CIRCULATION, 2013, 127 (03) :377-385

[10]

HUNT D, 1992, LANCET, V339, P753

← 1 2 3 →